On September 24, a multinational consortium of organizations in the cancer field is hosting the annual World Cancer Research Day, which aims to raise awareness about the importance of further developing and boosting cancer research as a crucial part of slowing the diseases’ progression and improving survival rates and quality of life for those affected.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Reagan-Udall Foundation for the FDA, with input from experts at FDA, launched Expanded Access eRequest to streamline expanded access for individual patients in non-emergency settings.
The COVID-19 pandemic has made 2020 a challenging year for everyone, including cancer care providers, many of whom have had difficulty obtaining Personal Protective Equipment (PPE) for their patients and staff during the pandemic. To help ease this burden on its members, the American Society of Clinical Oncology (ASCO) partnered with Project N95—a not-for-profit organization—to offer a discount on much-needed PPE for qualifying ASCO members in the United States.
The Association for Clinical Oncology (ASCO) held its first-ever virtual Advocacy Summit and online Week of Action September 9 – 18, 2020. The largest Advocacy Summit to date, 170 ASCO volunteer leaders and oncology care providers participated in 200 virtual meetings with Members of Congress and their staff to advocate for policies that would improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research. Participants represented 44 different states, as well as Puerto Rico and the District of Columbia.
The Centers for Medicare & Medicaid Services (CMS) finalized the Radiation Oncology (RO) model, a mandatory payment model that requires participation from radiotherapy (RT) providers and suppliers that furnish RT services within randomly selected core-based statistical areas (CBSAs)—which are linked to ZIP Codes.
On September 24, a multinational consortium of organizations in the cancer field will host the annual World Cancer Research Day, which aims to raise awareness about the importance of further developing and boosting cancer research as a crucial part of slowing the diseases’ progression and improving survival rates and quality of life for those affected. This is particularly important as the total number of cancer cases rising.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.
On September 13, President Trump signed an executive order (EO) aiming to address high prescription drug prices by tying payments for certain Medicare drugs to the costs the treatments sell for outside the United States (U.S.). According to the EO, prices for provider-administered drugs would be linked to a "most-favored-nation price" drawn from the lowest price among countries that have a similar per-capita gross domestic product.
The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.
On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
The Association for Clinical Oncology (ASCO) today released a statement regarding concerns that the U.S. Department of Health and Human Services (HHS) rescission of all guidance and informal issuances related to the Food and Drug Administration’s (FDA) current oversight of the premarket review and approval process for laboratory developed tests (LDTs) puts the safety of cancer treatments at risk.
On September 2, the Centers for Medicare & Medicaid Services (CMS) released updates to the Inpatient Prospective Payment System (IPPS) final rule for fiscal year 2021, including updates to Medicare payment policies and payment rates for most acute care hospitals. Notably, CMS finalized its proposal to establish a Medicare Severity Diagnosis Related Group (MS-DRG) for chimeric antigen receptor T-cell (CAR-T) services.
ASCO has been notified about a recent safety update relating to the drug COPIKTRATM (duvelisib) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program.
While cancer remains the second leading cause of death in high-income countries, cancer-related mortality has been steadily declining thanks to a wide range of advances. Today, ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, and co-authors Sharyl Nass, PhD, Michelle M. Le Beau, PhD, and Edward J. Benz, Jr., MD, highlight the major advances in cancer care over the last 50 years as part of a special series of articles in the New England Journal of Medicine commemorating the 50 year anniversary of the National Academy of Medicine.